Repligen (RGEN) Tops Q3 EPS by 14c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
October 28, 2021 7:30 AM EDTReports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77%Raises revenue guidance to $655-$665 million for full year 2021Completes acquisition of affinity ligands innovator Avitide Inc.
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2021. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2021, updates to our... More
